Jiudian Pharmaceutical announced that in the first three quarters of 2026, it achieved operating income of 2,049 billion yuan, a year-on-year decrease of 9.67%; net profit attributable to shareholders of listed companies was 240 million yuan, a year-on-year decrease of 40.96%; after deducting non-net profit of 230 million yuan, a year-on-year decrease of 41.22%. The third quarter of 2026 achieved operating income of 762 million yuan, an increase of 0.77% year on year; net profit to mother was 80.2402 million yuan, down 30.19% year on year. The decline in performance was mainly due to a year-on-year increase in the procurement price of the leading product loxoprofen sodium gel patch, management costs and financial expenses.

Disclaimer:Webull uses external vendor Google Translation Service for news translations where we endeavour to ensure these are correct, however, we recommend that you please double-check this information accordingly. Webull is not responsible for translation errors or issues.